BioAxone Therapeutic Inc. Company Profile

21:52 EDT 24th June 2018 | BioPortfolio

BioAxone’s strategy is to become the world’s dominant bio-pharmaceutical company targeting Rho and Rho-related pathways with the purpose of developing drugs that meet large unmet medical needs. Rho being a signaling pathway which plays a key role in many disease indications, BioAxone has successfully developed a protein based inhibitor for local acute administration, as well as a family of small molecule inhibitors with improved specificity and systemic formulation potential. Both compound families (protein and chemical analogs) are aimed at disease indications for which important medical needs exist but that are not addressed satisfactorily by existing approved therapies: Spinal Cord Injury (“SCI”), Age-related Macular Degeneration (“AMD”) and Glaucoma


7150 rue Frederick-Banting, Suite 200
H4S 2A1


Phone: (514) 282-9990
Fax: (514) 282-9990

News Articles [90 Associated News Articles listed on BioPortfolio]

BioAxone BioSciences Appoints Ronald S. Goldstein as CFO

- Brings Experience Across Full Spectrum of Corporate Finance – BioAxone BioSciences, Inc., an emerging clinical-stage biotechnology company focused on developing innovative...

Lisa McKerracher Invited Member and Speaker at Two Prestigious Universities

- Dr. McKerracher, CEO of BioAxone BioSciences, will be a member of the Leader’s Council at McGill University and a speaker at Rutgers University - BioAxone BioScienc...

Polypeptide Therapeutic Solutions and PMC Isochem collaborate

The two companies have signed a business and technology agreement to develop therapeutic polypeptides

Systematic treatment of periodontal disease: Advantage of further therapeutic approaches

(Institute for Quality and Efficiency in Health Care) An indication or hint of greater benefit was now shown for six instead of two therapeutic measures. This applies particularly to the attachment le...

New therapeutic target for rheumatoid arthritis

University of Birmingham Enterprise announces the formation of a new spinout company, Viatem Ltd, to develop and exploit the therapeutic potential of PEPITEM (Peptide Inhibitor of Trans-Endothelial Mi...

Looking for a Therapeutic Edge Among CDK Inhibitors

Whenever 3 agents joining the therapeutic armamentarium do so for similar indications with essentially identical mechanisms of action, it is reasonable to ask whether these agents have specific differ...

Preclinical characterisation of therapeutic antibodies

Even though the Shh pathway is mainly quiescent in adults, the safety of Shh-targeting with therapeutic antibodies was questioned initially because not only does the N-terminus of the Shh protein play...

Celebrating new therapeutic modalities

Last week Alnylam reported positive news on Phase 3 outcomes for their RNA interference (RNAi) therapy to treat patients with a rare genetic cause of amyloidosis with polyneuropathy (see here). I twee...

Drugs and Medications [0 Results]


PubMed Articles [705 Associated PubMed Articles listed on BioPortfolio]

The therapeutic discharge II: An approach to documentation in the setting of feigned suicidal ideation.

The therapeutic discharge of patients assessed as misrepresenting suicidal ideation, though in the best interests of the patient, physician, and health care system, is an inherently risk-assuming acti...

Client and therapist match on gender, age, and income: Does match within the therapeutic dyad predict early growth in the therapeutic alliance?

Because of the importance of the therapeutic alliance across psychotherapeutic treatments, it is important to study variables that predict the development of a positive therapeutic alliance. This stud...

A Systematic Review Of Salivary Versus Blood Concentrations Of Anti-Tuberculosis Drugs And Their Potential For Salivary Therapeutic Drug Monitoring.

Therapeutic drug monitoring is useful in the treatment of tuberculosis to assure adequate exposure, minimize antibiotic resistance, and reduce toxicity. Salivary therapeutic drug monitoring could redu...

Limitation of therapeutic effort in patients with bacteremia.

The limitation of therapeutic effort (LTE) depends on medical, ethical and individual factors. We describe the characteristics of patients with bacteremia in which it was decided to limit the therapeu...

Update on the role and therapeutic potential of polycomb repressive complexes in (biliary tract) cancer.

Clinical Trials [1852 Associated Clinical Trials listed on BioPortfolio]

Effects of Therapeutic Touch in Patients With Female Genital Neoplasia: a Randomized Controlled Clinical Trial

This is a randomized controlled prospective study on the use of therapeutic touch in patients diagnosed with gynecological cancer. The patients will be randomized into three groups: contro...

Platform Therapeutic Education in Heart Failure and Coronary Disease

A first therapeutic education is given before patient's discharge at the hospital, then a dedicated nurse follows patients through the phone,regularly according to patients' needs, continu...

Therapeutic Exercise in Cancer-Related Fatigue in Women After Breast Cancer Treatment

The main objective of this study is to determine whether the proposed program of therapeutic exercise is effective in improving fatigue and quality of life, more than the exercise unsuperv...

Therapeutic Angiotensin-(1-7) in Treating Patients With Sarcoma That is Metastatic or Cannot Be Removed by Surgery

RATIONALE: Therapeutic angiotensin-(1-7) may stop the growth of sarcoma by blocking blood flow to the tumor. PURPOSE: This phase II trial is studying the side effects of therapeutic angio...

Antibiotics Versus Therapeutic Ultrasound for Sinusitis

Question: Is the effect of therapeutic ultrasound equally effective to antibiotic for treatment of sinusitis? Design: A randomized clinical trial with concealed allocation, self-assessment...

Companies [851 Associated Companies listed on BioPortfolio]

BioAxone Therapeutic Inc.

BioAxone’s strategy is to become the world’s dominant bio-pharmaceutical company targeting Rho and Rho-related pathways with the purpose of developing drugs that meet large unmet medical needs. Rh...

BioAxone BioSciences, Inc.

BioAxone BioSciences is a clinical-stage biotechnology company developing innovative drugs to restore neurological function for patients with Spinal Cord Injuries (SCI) and other ...

The Therapeutic Goods Administration (TGA)

The Therapeutic Goods Administration (TGA) is a unit of the Australian Government Department of Health and Ageing. The TGA carries out a range of assessment and monitoring activities to ensure therape...

Therapeutic Proteins Ltd.,

Therapeutic Proteins Ltd., is a world class global developer and supplier of biosimilar recombinant therapeutic proteins. Manufactured in fully cGMP compliant facilities in Europe and North America, o...

Helios BioSciences

The quick selection at low cost of relevant therapeutic targets is one of today major challenges facing the Biotech companies and pharmaceutical industry. The evaluation of the genes involved in a giv...

More Information about "BioAxone Therapeutic Inc." on BioPortfolio

We have published hundreds of BioAxone Therapeutic Inc. news stories on BioPortfolio along with dozens of BioAxone Therapeutic Inc. Clinical Trials and PubMed Articles about BioAxone Therapeutic Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of BioAxone Therapeutic Inc. Companies in our database. You can also find out about relevant BioAxone Therapeutic Inc. Drugs and Medications on this site too.

Quick Search


Relevant Topic

Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...

Corporate Database Quicklinks

Searches Linking to this Company Record